Check-Cap was founded in 2005 with the vision of developing the world’s first ingestible imaging capsule system for colorectal cancer screening.
With offices in Israel and Boston, MA, Check-Cap employs an R&D team of world-class experts in a range of fields including physics, algorithms, software, hardware and clinical science.
From its inception, Check-Cap's solution was designed to overcome the significant barriers that deter patients from completing colorectal cancer (CRC) screening, such as bowel preparation, invasiveness and risk, sedation, and stool collection.
On February 24, 2015, Check-Cap successfully completed an Initial Public Offering in the United States and the listing of securities on the NASDAQ Capital Market.
Check-Cap continues to develop its breakthrough technology for CRC screening, with the aim of addressing the needs of adults between the ages of 50-75 who are not current with screening recommendations - nearly one-third of the eligible population in the U.S and greater than 60% of those outside the U.S.